BRIACELL THERAPEUTICS CORP C/WTS (TO PUR COM)(BCTXZ.US)

longbridge loading
Company Encyclopedia
View More
name
BRIACELL THERAPEUTICS CORP C/WTS (TO PUR COM)
BCTXZ.US
News
View More

BriaCell shows tumors regression in metastasized cancer patients with liver, brain involvement. Study details included.

BriaCell Therapeutics Corp., a clinical-stage biotechnology company listed on both Nasdaq (BCTX, BCTXW, BCTXZ, BCTXL) and TSX (BCT), has recently shared new images showcasing the successful treatment of metastatic breast cancer in patients with lesions in the eye, brain, liver, and spine. The company's Phase 2 study includes survival data on these patients and others, which has been previously disclosed. This development demonstrates the potential of BriaCell's immunotherapies to revolutionize cancer care.

Unusual Whales·
US
BCTX
+0.24%
US
BCTXZ
-2.72%
US
BCTXW
0.00%
Unusual Whales·
US
BCTX
+0.24%
US
BCTXZ
-2.72%
US
BCTXW
0.00%

BriaCell Therapeutics Reports Tumor Regression in Phase 2 Study of Bria-IMT for Metastatic Breast Cancer

BriaCell Therapeutics Corp. has reported tumor regression in its Phase 2 study of Bria-IMT™ for metastatic breast cancer. New clinical images show regression of metastatic lesions in various locations, with no treatment-related discontinuations reported. The study includes patients previously treated with other therapies. Bria-IMT™ is also in a pivotal Phase 3 trial and has received Fast Track Designation from the US FDA.

Reuters·
US
BCTXZ
-2.72%
US
BCTX
+0.24%
US
BCTXW
0.00%
Reuters·
US
BCTXZ
-2.72%
US
BCTX
+0.24%
US
BCTXW
0.00%

BriaCell Reports Extended Survival in Phase 2 Metastatic Breast Cancer Trial

BriaCell Therapeutics Corp. has reported positive Phase 2 clinical trial results for its Bria-IMT™ regimen in metastatic breast cancer patients. Out of 54 heavily pre-treated patients, 9 remain alive 18 to 47 months post-enrollment, surpassing survival benchmarks for standard therapies. The median overall survival for patients treated since 2022 was 15.6 months, with 52% surviving one year and 32% surviving two years. No treatment-related discontinuations were reported, and results will be confirmed in an ongoing Phase 3 study focusing on overall survival as the primary endpoint.

Reuters·
US
BCTXW
0.00%
US
BCTXZ
-2.72%
US
BCTX
+0.24%
Reuters·
US
BCTXW
0.00%
US
BCTXZ
-2.72%
US
BCTX
+0.24%

Stocks in Play: BriaCell Therapeutics Corp.

10:50 AM EST - BriaCell Therapeutics Corp. : Announces new positive Phase 2 survival data highlighting multiple patients surpassing expected benchmarks for metastatic breast cancer and survival length over 18 months in nine cases as of their last assessment. BriaCell Therapeutics Corp. shares T.BCT are trading up $0.05 at $6.43.

Baystreet·
US
BCTXZ
-2.72%
US
BCTX
+0.24%
US
BCTXW
0.00%
Baystreet·
US
BCTXZ
-2.72%
US
BCTX
+0.24%
US
BCTXW
0.00%

BriaCell reports extended >18-47 months survival in Phase 2 metastatic breast cancer patients, with 9 cases surpassing 18 months.

Philadelphia and Vancouver, BC - On January 27, 2026, BriaCell Therapeutics Corp revealed encouraging Phase 2 survival data for their immunotherapies. The clinical-stage biotechnology company reported that several patients with metastatic breast cancer have exceeded the typical survival expectations, with 9 individuals surpassing the 18-month milestone in their latest evaluations. BriaCell's stock is listed under Nasdaq as BCTX, BCTXW, BCTXZ, BCTXL, and under TSX as BCT.

Unusual Whales·
US
BCTXW
0.00%
US
BCTX
+0.24%
US
BCTXZ
-2.72%
Unusual Whales·
US
BCTXW
0.00%
US
BCTX
+0.24%
US
BCTXZ
-2.72%
© 2026 Longbridge｜Disclaimer